A novel fast gas chromatography-mass spectrometry (FGC-MS) analytical method for benzoylecgonine (BZE) has been developed to improve the efficiency of specimen analysis without diminishing the reliability of metabolite identification and quantification. Urine specimens were spiked with deuterated internal standard (BZE-d~), subjected to solid-phase extraction, and derivatized with pentafluoropropionic anhydride (PFPA) and pentafluoropropanol (PFPOH). The pentafluoropropyl ester derivative of BZE was identified and quantified using both a standard GC-MS method and the newly developed FGC-MS method. Shorter GC analyte retention times were made possible in the FGC-MS method by employing a 220-volt GC oven controller, which allowed an increased temperature ramp rate. The FGC-MS method was linear between 25 and 10,000 ng/mL of BZE yielding a correlation coefficient of 0.9994. The intra-assay precision of a 100 ng/mL BZE standard (n = 15) yielded an average concentration of 99.7 ng/mL and a coefficient of variation of 1.2%. The interassay precision of 21 sets of 50, 100, and 125 ng/mL BZE controls was found to be acceptable, with coefficients of variation less than 2.4%. No interference was observed when the FGC-MS method was challenged with cocaine, ecgonine, ecgonine methyl ester, and nine other drugs of abuse. Analysis of presumptively positive specimens (n = 146) by both analytical methods yielded comparable results with a correlation coefficient of 0.996. The FGC-MS method, when compared with a standard GC-MS method, reduces total assay time by approximately 50% while demonstrating comparable reliability.
drug for the first time; the average age of new cocaine initiates was 20.0 years (1) . According to the 2004 National Household Survey of Drug Abuse, 5.7 million (2.4%) Americans ages 12 and older have used cocaine in the past year (1) . Data from the Drug Abuse Warning Network (DAWN) shows that in 2001, 30% of the 638,484 emergency department drug-related episodes were due to cocaine (2) . In addition to causing serious health problems, cocaine abuse costs society billions of dollars annually as a result of lost job productivity, cocaine-related crimes, and the funding of cocaine-use prevention programs (3) . Cocaine use by members of the United States Armed Forces is detrimental to military readiness, as well as service member health and mission achievement.
One of the ways to deter the use of cocaine and other drugs of abuse in the workforce is by monitoring use through testing of employees and military personnel (4) . The efficacy of the military forensic drug testing program is evident in the dramatic decrease in self-reported illicit drug use from 27.6% (1980) to 3.4% (2002) , as shown in the Department of Defense Survey of Health Related Behaviors Among Military Personnel (5) . Moreover, the percentage of individuals that tested positive for illicit drugs decreased from 8% to less than 1% during the same period .
Forensic analysis of urine specimens for cocaine under Department of Defense (6, 7) or Department of Health and Human Services guidelines (8) require testing by two different scientific technologies, such as immunoassay and gas chromatography-mass spectrometry (GC-MS). To date, technology has been developed that has increased the efficiency and cost effectiveness of both of these testing methodologies in detecting and quantifying the major metabolite of cocaine, benzoylecgonine (BZE) (9) (10) (11) (12) (13) (14) (15) .
The use of solid-phase extraction columns and the Speedisk 48 positive-pressure extraction manifold have been proven to be practical and efficient methods for extracting BZE from urine (16, 17) . A method employing the Speedisk 48 positive-pressure extraction manifold has been shown to decrease extraction time by as much as 50% compared to liquid-liquid extraction methods or other automated solid-phase extraction methods. Improvements in gas chromatography include electronic pressure control, which allows head pressures to be programmed into the method. This enhancement results in improved chromatography and faster analysis times. Analysis times were further decreased by the introduction of a 220 Volt GC oven controller, which provides the power capacity to use faster oven temperature ramps (18) . The use of a 220-volt GC oven controller for fast GC-MS (FGC-M8) has been shown to improve the efficiency of 11-nor-A9-tetrahydrocannabinol-9-carboxylic acid (THCA) and amphetamine analogue analyses by significantly decreasing GC-MS analysis times (19, 20) .
The purpose of this study was to develop an efficient FGC-MS method for the analysis of BZE in human urine specimens.
Methods

Materials
Controls, specimens, and standards were prepared by spiking certified drug-free urine (Roche Diagnostics, Indianapolis, IN) with BZE (Cerilliant, Round Rock, TX). Working internal standard stock solutions containing 2.00 t~g/mL of BZE-d8 (Cerilliant) were prepared in methanol (Fisher Chemical, Fairlawn, N J). All standards and controls were prepared from different vials of BZE and were certified by the standard GC-MS procedure. High-performance liquid chromatography (HPLC)/ GC-MS-grade ethyl acetate and methylene chloride; HPLCgrade monobasic potassium phosphate; and ACS-grade hydrochloric acid, pentafluoropropionic anhydride (PFPA), and pentafluoropropanol (PFPOH) were purchased from SigmaAldrich (St. Louis, MO). High-resolution GC/HPLC trace-grade methanol was purchased from Pharmco Products (Brookfield, CT), and ammonium hydroxide was purchased from Mallinckrodt (Phillipsburg, N J). For the interference studies, pseudoephedrine, ephedrine, ecgonine, and ecgonine methyl ester (EME) were purchased from Sigma-Aldrich. 3,4-Methylenedioxymethamphetamine (MDMA), amphetamine, 6-monoacetylmorphine (6-AM), cocaine, phencyclidine (PCP), and lysergic acid diethylamine (LSD) were purchased from Cerilliant, and THCA was purchased from the Research Triangle Institute (Research Triangle Park, NC).
Extraction and derivatization
Samples were prepared by pipetting 2.0-mL aliquots of each control or specimen into 50-mL polypropylene conical tubes (Biomedical Polymers, Garner, MA). To each 2.0-mL aliquot, 100 lJL of internal standard (BZE-d8 at 2.00 lJg/mL) and 100 I~L of 1.0M potassium phosphate buffer (pH 6.0) were added. Samples were poured into 6 mL/50 mg cation-exchange/mixed bed Cerex | Polychrom CLIN II extraction columns and placed on a Speedisk | 48 Pressure Processor (SPEware, San Pedro, CA). The flow of the urine through the columns was facilitated using nitrogen gas (99.9% purity, Airgas, Radnor, PA) at a positive pressure of 2-3 psi. The columns were sequentially washed with 1 mL each of deionized water, 0.1M HC1, methanol, and ethyl acetate and then were dried for 2 rain at 25 psi. BZE and the internal standard (BZE-d8) were eluted from the column by gravity flow using methylene chloride/methanol/ammonium hydroxide (70:25:5, v/v/v). The extracts were dried under nitrogen at 48-50~ using a Caliper LifeSciences TurboVap TM LV Evaporator (Hopkinton, MA).
The extracts of BZE and internal standard were derivatized to their pentafluoropropyl esters by adding 50 I~L of PFPA and 25 I~L of PFPOH to each and incubating the reactants at 60-70~ for 10 rain (17) . The specimens were then dried under nitrogen gas, reconstituted with 60 tJL of ethyl acetate, and transferred to automated liquid sampler vials.
GC-MS analysis
GC-MS analyses were performed using an Agilent 6890N GC (Palo Alto, CA) equipped with a 7683 autoinjector and DB5ms bonded-phase capillary GC column (15 m x 0.25-mm i.d., 0.25-1Jm film thickness) and a 5973N mass selective detector. A 220-V GC oven controller was used for FGC-MS conditions, whereas a 110-V GC controller was used for standard GC-MS conditions. The FGC-MS and standard GC-MS methods used helium as the carrier gas. Assays were typically run with a split ratio of 1:15, an initial column pressure of 8 psi, and a constant helium flow rate of approximately 1 mL/min. TargetDB version 4.11 software (Thermo Electron, Waltham, MA) was used for data reduction and report generation.
All specimens were analyzed in the selected ion monitoring (SIM) mode using the ions listed in Table I . For both analytical procedures, the 50 ng/mL BZE control was used to establish the minimum injection volume (0.5 to 2.0 IJL) and electron multiplier setting (0 to 600 V over autotune) that resulted in all monitored ions having area counts of 500 or greater.
For the standard GC-MS method, temperatures were adjusted to obtain a retention time between 3.0 and 4.5 rain for the pentafluoropropyl ester derivative of BZE. An initial GC oven temperature of approximately 205~ was held until 0.5 rain after the BZE derivative eluted and then ramped at 25~ to a final temperature of 275~ which was then held for 1.0 min. The injector temperature was set at 5-10~ above the initial oven temperature, and the auxiliary transfer line temperature was set at 290~ Dwell times were set at 70 ms for all monitored ions.
For the FGC-MS method, temperatures were adjusted to obtain a retention time between 1.5 and 2.1 min for the pentafluoropropyl ester derivative of BZE. An initial GC oven temperature of approximately 200~ was held for 1.0 min and then ramped at 40~ to a final temperature of 275~ The injector temperature was set at approximately 280~ and the auxiliary transfer line temperature was set at approximately 285~ Dwell times were set at 15 ms for all monitored ions. The shorter dwell time was required in order to maintain sufficient scans across the narrower peaks produced by the FGC-MS analytical method. Calibration and controls These assays were calibrated at the current military cutoff concentration using a 100 ng/mL BZE calibration standard. Quantification of BZE in specimens and controls was calculated by dividing the m/z 421/429 response factor of the specimen by the m/z 421/429 response factor of the calibrator. The qualifier ion ratios were m/z 272/421 and m/z 300/421 for the analyte and m/z 303/429 for the internal standard (Table I) . Qualitative identification of the specimen required that the retention time be within 2% and the qualifier ions abundance ratios be within 20% of the 100 ng/mL calibration standard. Each analytical batch contained open controls at 0 ng/mL and 50 ng/mL BZE and blind controls at 0 ng/mL and 125 ng/mL BZE to monitor the accuracy of the 100 ng/mL cutoff concentration. Quantifications of controls were required to be within 20% of the target concentration and the negative controls were required to be less than the instrument's limit of detection (LOD) for the analyte (Table II) . The 100 ng/mL calibrator was reinjected at the end of each analytical run to monitor any change in instrument performance.
Results and Discussion
A retention time between 1.5 and 2.1 rain was obtained for the pentafluoropropyl ester derivatives of BZE and BZE-ds when analyzed by FGC-MS. This represents a time savings of 40-50% compared with a retention time of 3.0 to 4.5 rain ob- Figure 1 . Total ion chromatogram and chromatograms of the selected ions for a 100 ng/mL BZE calibration standard including 100 ng/mL of BZE-d8 internal standard. tained using the standard GC-MS method. The timesavings is even more dramatic when the run time of approximately 3.0 min for the FCG-MS method is compared with the run time of approximately 7.5 rain for the standard GC-MS method. Chromatographic quality, baseline resolution, and sensitivity were not compromised despite the shorter retention time achieved by FCG-MS. Figure 1 shows a typical total ion chromatogram and chromatograms for the selected ions for a 100 ng/mL BZE calibration standard containing 100 ng/mL of BZE-d8 internal standard.
Linearity and precision
Four replicates of spiked urine samples containing 12.5, 25, and 40 ng/mL BZE were analyzed to determine the limit of detection (LOD) and limit of quantitation (LOQ) for these methods. The LOD was defined as the lowest concentration of BZE that resulted in acceptable chromatographic peaks with a retention time within 2% and qualifier ion abundance ratios within 20% of the 100 ng/mL BZE calibration standard. The LOQ was defined as the lowest concentration of BZE that quantified within 20% of the target concentration and also met the LOD criteria. For the FGC-MS and the standard GC-MS analytical methods, the LOD and LOQ were determined to be 25 ng/mL BZE.
Four replicates of spiked urine specimens containing 1000, 2000, 5000, 10,000, and 20,000 ng/mL BZE were analyzed to determine the upper limit of linearity (ULOL) for these methods. A ULOL of 10,000 ng/mL BZE was determined as the highest concentration of BZE that quantified within 15% of the target concentration and had acceptable chromatographic peaks with retention times within 2% and qualifier ion abundance ratios within 20% of the 100 ng/mL BZE calibration standard. The assay linearity limits are summarized in Table II . Intra-assay precision was determined by analyzing 15 replicates of the 100 ng/mL BZE calibration standard. The quantifications obtained for the intra-assay precision ranged from 96.8 to 101.5 ng/mL BZE with a mean of 99.7 ng/mL and a coefficient of variation of 1.2%. Internal standard signal intensity of the m/z 429 ion area averaged 5500 + 785 for these 15 replicates.
The interassay precision for the FGC-MS and GC-MS methods was determined from the quantitative results obtained from 21 analytical batches for the 50 ng/mL BZE open control, 125 ng/mL BZE blind control and reinjection of the 100 ng/mL BZE calibration standard. As shown in Table III , the range and mean BZE concentration for both methods are similar, with coefficients of variation less than 2.4%.
Peak symmetries for each of the chromatographic peaks of the monitored ions were calculated using the TargetDB data reduction software. The peak symmetry values (Wb/W a) were calculated by setting a vertical line at the peak apex and then dividing the distance from the peak trailing edge to the vertical line at 10% peak height (Wb) by the distance from the peak leading edge to the vertical line at 10% peak height (Wa). Table IV summarizes peak symmetry data from 21 assays for all of the monitored ions of the 50 ng/mL BZE control. All peak symmetries were well within the Laboratory's 0.5 to 2.0 ac- ceptance criteria and were indicative of the Gaussian-shaped peaks produced by the FGC-MS method. As BZE concentrations increased, the peak symmetry decreased, and at 20,000 ng/mL BZE, peak symmetry was near the lower limit of the acceptance range.
Specificity
Specificity of the BZE FGC-MS analytical method was investigated by analyzing cocaine, ecgonine, EME, ephedrine, pseudoephedrine, MDMA, amphetamine, PCP, 6-AM, THCA, and LSD at the concentrations listed in Table V . The potential for compounds to interfere with the analysis of BZE in the FGC-MS analytical method was investigated by analyzing the compounds listed in Table V in the presence of 40, 300, or 600 ng/mL of BZE. The FGC-MS analytical method proved to be specific for BZE as none of the tested compounds had chromatographic peaks at the retention time of BZE. None of the compounds tested interfered with the quantification or identification of BZE or the internal standard (BZE-d8); all of the monitored ions for BZE and internal standard were well-resolved and symmetric.
47.7-52.3 Comparison study
98.7-104
A comparative study of 146 authentic human 123-133 urine specimens that had screened above the 150 ng/mL cutoff by immunoassay (Dade Behring Syva Emit II Plus Cocaine Metabolite Assay) (21) was performed using the standard GC-MS and the FGC-MS methods. The specimen extracts were analyzed by both methods in 21 different batches. Those specimens that exhibited an immunoassay response of 300 or greater (150 ng/mL of BZE = 100 immunoassay normalized units) were diluted 10-fold prior to analysis. Of the 146 specimens analyzed, 12 samples were found to be below the 100 ng/mL BZE cutoff by both analytical methods. The concentration of BZE detected by the FGC-MS method ranged from 34 to 7290 ng/mL. Linear regression analysis of the two sets of values yielded an r 2 of 0.996 and a slope of 0.909 as shown in Figure 2 . Differences in observed concentration between the FGC-MS and standard GC-MS method varied from +13.1% to -19.3%. Analysis of variance (F = 1.21) and linear regression failed to demonstrate any statistical difference between the quantitative results generated for the spec- imens as assayed by both methods. At higher concentrations the FGC-MS method tended to give slightly lower values compared to the standard GC-MS method. For the 115 specimens that quantified below 1000 ng/mL, the slope was 0.971 with an r 2 of 0.993. The data demonstrate the reliability of both analytical methods for analyzing urine specimens for BZE.
